Research indicates that GLP-1 drugs like Ozempic and Wegovy may offer benefits beyond weight loss, including reduced anxiety, binge eating symptoms, and impulsivity.
Key facts
- •Semaglutide use was linked to a 42% lower risk of worsening mental illness in a study published in The Lancet Psychiatry.
- •A meta-analysis of 25 trials found moderate reductions in binge eating symptoms among GLP-1 users.
- •The association between impulsivity and violent behavior was 62% weaker in current GLP-1 users compared to former users.
- •Research presented at ENDO 2026 showed that setting personal weight loss goals improved outcomes for patients using tirzepatide.
- •GLP-1 medications may influence reward processing by crossing the blood-brain barrier.
Recent studies suggest that GLP-1 medications, commonly used for diabetes and weight management, may provide mental health benefits. Research published in journals such as The Lancet Psychiatry and eClinical Medicine indicates these drugs are associated with lower risks of worsening depression and anxiety, as well as reductions in binge eating symptoms and impulsive behaviors.
By the numbers
Mental Health and Binge Eating
A study in The Lancet Psychiatry found that semaglutide use was associated with a 42% lower risk of worsening mental illness compared to periods without the medication. Additionally, a systematic review of 25 randomized controlled trials showed that GLP-1 medications consistently reduced core symptoms of binge eating disorder, including emotional eating and loss of control.
Impulsivity and Food Noise
Research published in Criminology found that the link between impulsivity and violent behavior was approximately 62% weaker among current GLP-1 users compared to former users. Separately, an observational study of 417 adults indicated that combining GLP-1 medication with a digital behavioral weight management program resulted in a greater reduction of 'food noise'—intrusive thoughts about food—than behavioral programs alone.
Goal Setting and Weight Loss
A study presented at ENDO 2026 involving over 80,000 individuals found that patients who set personal weight loss goals achieved a higher percentage of weight loss while using tirzepatide. The findings suggest that active goal setting and lifestyle changes can enhance the effectiveness of these medications.
Advertisement
This article was independently rewritten by ManyPress editorial AI from reporting originally published by Healthline.
